BTG Pays 160 Million Pounds for Rival Biocompatibles

BTG, the pharmaceutical group perhaps best known for its varisolve varicose veins treatment, is paying around £160 million to buy drug device group Biocompatibles, adding oncology products to its portfolio.
Guardian